Literature DB >> 31971613

Current multidisciplinary management of brain metastases.

Michael J Moravan1,2, Peter E Fecci3, Carey K Anders4, Jeffrey M Clarke4, April K S Salama4, Justus D Adamson1, Scott R Floyd1, Jordan A Torok1, Joseph K Salama1,2, John H Sampson1,3, Paul W Sperduto5,6, John P Kirkpatrick1,3.   

Abstract

Brain metastasis (BM), the most common adult brain tumor, develops in 20% to 40% of patients with late-stage cancer and traditionally are associated with a poor prognosis. The management of patients with BM has become increasingly complex because of new and emerging systemic therapies and advancements in radiation oncology and neurosurgery. Current therapies include stereotactic radiosurgery, whole-brain radiation therapy, surgical resection, laser-interstitial thermal therapy, systemic cytotoxic chemotherapy, targeted agents, and immune-checkpoint inhibitors. Determining the optimal treatment for a specific patient has become increasingly individualized, emphasizing the need for multidisciplinary discussions of patients with BM. Recognizing and addressing the sequelae of BMs and their treatment while maintaining quality of life and neurocognition is especially important because survival for patients with BMs has improved. The authors present current and emerging treatment options for patients with BM and suggest approaches for managing sequelae and disease recurrence.
© 2020 American Cancer Society.

Entities:  

Keywords:  brain metastases; immunotherapy; laser-interstitial thermal therapy; radiation therapy; radionecrosis; stereotactic radiosurgery

Year:  2020        PMID: 31971613     DOI: 10.1002/cncr.32714

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  23 in total

1.  Validation of a Graded Prognostic Model in Patients With Brain Metastases Treated With Whole-brain Radiotherapy Instead of Radiosurgery.

Authors:  Carsten Nieder; Bård Mannsåker; Rosalba Yobuta
Journal:  In Vivo       Date:  2021 May-Jun       Impact factor: 2.155

2.  Role of whole brain radiotherapy in the management of infratentorial metastases from lung and breast cancer.

Authors:  Bernardo Cacho-Díaz; Alejandra Alvarez-Alvarez; Karen Salmerón-Moreno; Oscar Rodríguez-Mayoral; Bernardino Gabriel Santiago-Concha; Oscar G Arrieta Rodríguez
Journal:  Rep Pract Oncol Radiother       Date:  2021-08-12

3.  Significant survival improvements for patients with melanoma brain metastases: can we reach cure in the current era?

Authors:  Assaf Berger; Kenneth Bernstein; Juan Diego Alzate; Reed Mullen; Joshua S Silverman; Erik P Sulman; Bernadine R Donahue; Anna C Pavlick; Jason Gurewitz; Monica Mureb; Janice Mehnert; Kathleen Madden; Amy Palermo; Jeffrey S Weber; John G Golfinos; Douglas Kondziolka
Journal:  J Neurooncol       Date:  2022-06-04       Impact factor: 4.130

4.  A clinically compatible drug-screening platform based on organotypic cultures identifies vulnerabilities to prevent and treat brain metastasis.

Authors:  Lucía Zhu; Diana Retana; Pedro García-Gómez; Laura Álvaro-Espinosa; Neibla Priego; Mariam Masmudi-Martín; Natalia Yebra; Lauritz Miarka; Elena Hernández-Encinas; Carmen Blanco-Aparicio; Sonia Martínez; Cecilia Sobrino; Nuria Ajenjo; Maria-Jesus Artiga; Eva Ortega-Paino; Raúl Torres-Ruiz; Sandra Rodríguez-Perales; Riccardo Soffietti; Luca Bertero; Paola Cassoni; Tobias Weiss; Javier Muñoz; Juan Manuel Sepúlveda; Pedro González-León; Luis Jiménez-Roldán; Luis Miguel Moreno; Olga Esteban; Ángel Pérez-Núñez; Aurelio Hernández-Laín; Oscar Toldos; Yolanda Ruano; Lucía Alcázar; Guillermo Blasco; José Fernández-Alén; Eduardo Caleiras; Miguel Lafarga; Diego Megías; Osvaldo Graña-Castro; Carolina Nör; Michael D Taylor; Leonie S Young; Damir Varešlija; Nicola Cosgrove; Fergus J Couch; Lorena Cussó; Manuel Desco; Silvana Mouron; Miguel Quintela-Fandino; Michael Weller; Joaquín Pastor; Manuel Valiente
Journal:  EMBO Mol Med       Date:  2022-02-17       Impact factor: 12.137

5.  Central Nervous System Distribution of the Ataxia-Telangiectasia Mutated Kinase Inhibitor AZD1390: Implications for the Treatment of Brain Tumors.

Authors:  Surabhi Talele; Wenjuan Zhang; Jiajia Chen; Shiv K Gupta; Danielle M Burgenske; Jann N Sarkaria; William F Elmquist
Journal:  J Pharmacol Exp Ther       Date:  2022-08-05       Impact factor: 4.402

6.  Local control and radionecrosis of brain metastases from non-small-cell lung cancer treated by hypofractionated stereotactic radiotherapy: Evaluation of predictive factors.

Authors:  Brice Leyrat; Toufic Khalill; Jean-Jacques Lemaire; Melanie Casile; Ioana Molnar; Véronique Dedieu; Vincent Chassin; Guillaume Dupic; Aurélie Bellière; Xavier Durando; Michel Lapeyre; Pierre Verrelle; Julian Biau
Journal:  Clin Transl Radiat Oncol       Date:  2022-06-01

7.  Clinical outcomes of patients with multiple courses of radiosurgery for brain metastases from non-small cell lung cancer.

Authors:  Won-Jae Lee; Jung-Won Choi; Doo-Sik Kong; Ho Jun Seol; Do-Hyun Nam; Jung-Il Lee
Journal:  Sci Rep       Date:  2022-06-23       Impact factor: 4.996

8.  Socioeconomic Disparities in Brain Metastasis Survival and Treatment: A Population-Based Study.

Authors:  Adrian Rodrigues; Guan Li; Hriday Bhambhvani; Melanie Hayden-Gephart
Journal:  World Neurosurg       Date:  2021-11-14       Impact factor: 2.210

Review 9.  The Role of Stereotactic Biopsy in Brain Metastases.

Authors:  Kenny K H Yu; Ankur R Patel; Nelson S Moss
Journal:  Neurosurg Clin N Am       Date:  2020-08-14       Impact factor: 2.509

Review 10.  Next-generation immunotherapies for brain metastatic cancers.

Authors:  María López Vázquez; Wanlu Du; Nobuhiko Kanaya; Yohei Kitamura; Khalid Shah
Journal:  Trends Cancer       Date:  2021-03-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.